Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose

Samo registrirani uporabniki lahko prevajajo članke

Prijava / prijava

Povezava se shrani v odložišče

StanjeDokončano

Sponzorji

University of Aarhus

KLINIČNO PRESKUŠANJE: NCT01919788

BioSeek: nct01919788

Ključne besede

Povzetek

Diabetes mellitus type I (DMI) is characterized by lack of endogenous insulin and these patients are 100% dependent on insulin substitution to survive. Diabetes mellitus type II (DMII) is characterized by reduced insulin sensitivity and sometimes also reduced insulin production, thus patients with DMII might also be dependent on insulin substitution.

Insulin is produced in- and secreted from the pancreas when blood glucose concentration rises during- and after a meal. Insulin increases cellular uptake of glucose leading to lower blood glucose concentration. Substitution with insulin is/can be necessary in DM, but at the same time it induces the risk of hypoglycemia. This makes treatment with insulin a balancing act between hyper- and hypoglycemia.

A hypoglycemic episode is a dreaded consequence of insulin overdosing, and also a very frequent reason for hospital admission in patients with DM. Examples of hypoglycemic symptoms may be; shaking, a sense of hunger, sweating, irritability progressing to lack of relevant cerebral responses and eventually coma, convulsions and possibly death. People with diabetes lose the ability to sense of low blood glucose with time, because of a lack of appropriate counter-regulatory responses, hereby increasing the risk of severe hypoglycemia. Understanding normal physiologic counter regulatory mechanisms during hypoglycemia is of major importance to patients with DM and has the potential to change medical treatment in diabetes, to reduce the risk of hypoglycemia.

Hypothesis: Hypoglycemia counteracts insulin signaling via hormone-dependent intracellular counter-regulatory mechanisms, involving phosphorylation of specific signaling proteins.

Aim: To define counter-regulatory mechanisms in muscle- and fat tissue during hypoglycemia, and to investigate the effect of insulin on lipid metabolism in healthy- and type I diabetic subjects.

Datumi

Nazadnje preverjeno:	08/31/2019
Prvič predloženo:	08/04/2013
Predviden vpis oddan:	08/06/2013
Prvič objavljeno:	08/08/2013
Zadnja posodobitev oddana:	09/24/2019
Zadnja posodobitev objavljena:	09/26/2019
Dejanski datum začetka študija:	07/31/2013
Predvideni datum primarnega zaključka:	03/31/2014
Predvideni datum zaključka študije:	03/31/2014

Stanje ali bolezen

Diabetes Mellitus Type I

Hypoglycemia

Intervencija / zdravljenje

Drug: Insulin (Insuman Rapid)

Drug: Insulin and glucose

Other: Control

Faza

Skupine rok

Roka	Intervencija / zdravljenje
Placebo Comparator: Control No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice.	Other: Control
Experimental: Insulin Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
Experimental: Insulin and glucose Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm. Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice	Drug: Insulin and glucose

Merila upravičenosti

Starost, primerna za študij	18 Years Za 18 Years
Spol, upravičen do študija	Male
Sprejema zdrave prostovoljce	Da
Merila	- BMI > 19 and < 26 - Written Consent Exclusion Criteria: - Epilepsy - Cardiac arrythmia - Ischemic heart disease - Other medical illness

Izid

Primarni izidni ukrepi

1. Insulin and growth hormone signalling, expressed as CHANGE in phosphorylation of intracellular target proteins and mRNA expression of target genes in muscle- and fat-tissue. [Biopsies obtained on each study day (arm). Muscle biopsies: time (t)= -30min, t= 30min and t= 75min. Fat biopsies: t= 30min and t= 75min]

Change in phosphorylation of target proteins and mRNA expression of target genes assessed with western blotting technique.

Ukrepi sekundarnega rezultata

1. Intracellular markers of lipid metabolism in muscle- and fat tissue biopsies. [Biopsies obtained on each study day (arm). Muscle biopsies: time (t)= -30min, t= 30min and t= 75min. Fat biopsies: t= 30min and t= 75min]

Assessed by Western blotting.

2. Metabolism. [measured twice on each study day (arm) at t= -30-0 min. and t= 50-80 min.]

Assessment of glucose metabolism by forearm pletysmography and heated hand technique (duration of pletysmography = 30 min.)

3. Ghrelin [Measured at t = -30min., t=0min, t=15min, t= 30min., t=45min., t=60min., t= 75min., t=90min. and t=105min. on each study day (arm)]

4. Metabolism [once per study day (arm): t 45min - 105min.]

A palmitic acid tracer will be given once per trial day to estimate fatty acid metabolism. Duration 1 hour.

Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose

Ključne besede

epileptični krč

sladkorna bolezen tipa 1

sladkorna bolezen tipa 2

sladkorna bolezen

insulin resistance

hipoglikemija

antidiabetik